GGM Wealth Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
$480K Sell
20,816
-294
-1% -$7.69K 0.27% 76
2024
Q4
$560K Buy
21,110
+187
+0.9% +$5.07K 0.29% 70
2024
Q3
$605K Buy
20,923
+600
+3% +$17.5K 0.26% 69
2024
Q2
$569K Buy
20,323
+60
+0.3% +$1.65K 0.26% 68
2024
Q1
$543K Sell
20,263
-4,539
-18% -$126K 0.25% 69
2023
Q4
$681K Sell
24,802
-3,853
-13% -$116K 0.28% 68
2023
Q3
$950K Sell
28,655
-6,975
-20% -$247K 0.41% 49
2023
Q2
$1.28M Buy
35,630
+173
+0.5% +$6.73K 0.52% 42
2023
Q1
$1.45M Buy
35,457
+59
+0.2% +$2.55K 0.83% 30
2022
Q4
$1.8M Buy
35,398
+16
+0% +$767 0.93% 27
2022
Q3
$1.61M Buy
35,382
+2,138
+6% +$104K 0.87% 27
2022
Q2
$1.73M Buy
33,244
+29
+0.1% +$1.48K 0.97% 24
2022
Q1
$1.67M Buy
33,215
+8,403
+34% +$436K 0.83% 27
2021
Q4
$1.41M Buy
24,812
+16
+0.1% +$793 1.12% 22
2021
Q3
$1.07M Buy
24,796
+97
+0.4% +$4.3K 0.85% 30
2021
Q2
$996K Buy
24,699
+84
+0.3% +$3.27K 0.85% 31
2021
Q1
$951K Buy
24,615
+38
+0.2% +$1.35K 0.76% 30
2020
Q4
$905K Buy
+24,577
New +$901K 0.89% 27

Other funds holding PFE

GGM Wealth Advisors's PFE Position: Q1 2025 in Review

GGM Wealth Advisors reduced its Pfizer (PFE) stake by 1.4% in Q1 2025, selling an estimated $7.69K and leaving 20,816 shares worth $480K. The position accounts for 0.27% of the portfolio, ranked #76.

GGM Wealth Advisors first reported a position in PFE in Q4 2020 and has held it in 18 quarters since. The position peaked at $1.8M in Q4 2022. 2,931 funds tracked by Wall St. Rank hold PFE as of Q1 2025.

  • GGM Wealth Advisors held 20,816 shares of Pfizer worth $480K as of Q1 2025.
  • GGM Wealth Advisors sold 294 Pfizer shares in Q1 2025, an estimated $7.69K.
  • Pfizer made up 0.27% of GGM Wealth Advisors's portfolio in Q1 2025, its #76 holding.
  • GGM Wealth Advisors first reported a position in Pfizer in Q4 2020 and has held it in 18 quarters since.
  • GGM Wealth Advisors's Pfizer position peaked at $1.8M in Q4 2022.
  • 2,931 funds tracked by Wall St. Rank held Pfizer as of Q1 2025.

Based on GGM Wealth Advisors's 13F filing for Q1 2025, filed 1 May 2025.